Welcome to our dedicated page for LEMAITRE VASCULAR SEC filings (Ticker: LMAT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on LEMAITRE VASCULAR's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into LEMAITRE VASCULAR's regulatory disclosures and financial reporting.
LeMaitre Vascular reported higher results for the quarter and six months ended June 30, 2026. Quarterly net sales were $70.4 million, up 10% year over year, with net income of $17.1 million and diluted EPS of $0.74. For the first half, net sales reached $136.9 million, also up 10%, and net income was $32.7 million with diluted EPS of $1.42. Growth was driven by higher selling prices, increased volumes, and stronger graft and shunt sales, while catheters declined.
Profitability improved, with gross margin rising to 72.1% in the quarter and 72.4% year-to-date, helped by pricing, product mix, and lower shipping costs. At June 30, 2026, cash and cash equivalents were $26.6 million and short-term marketable securities $349.6 million, against $172.5 million of 2.50% convertible senior notes due 2030. Operating cash flow for the first half was $31.1 million. The company paid $0.50 per share in cash dividends year-to-date and has a $100 million share repurchase authorization in place with no repurchases yet.
LeMaitre Vascular reported strong preliminary, unaudited Q2 2026 results. Net sales were about $70.4M versus $64.2M a year earlier, with net income of $17.1M and diluted EPS of $0.74 versus $0.60. Gross margin reached 72.1%, up 210 bps, and adjusted EBITDA was $22.8M, up 20%.
Growth was led by Artegraft sales up 34%, record grafts, shunts and patches, and double-digit gains in EMEA and APAC. Organic growth excluding catheters was 12%; catheters declined 11% after prior-year recall overstocking. Cash and short-term marketable securities totaled roughly $376M and stockholders’ equity was $420.3M.
The board declared a $0.25 per-share quarterly dividend payable September 3, 2026 and previously authorized up to $100M of share repurchases through February 2027. Guidance calls for 2026 sales of $274.3M–$278.3M (midpoint $276.3M, about 11% growth) and EPS of $2.84–$2.94 (midpoint $2.89), implying 15% GAAP and 21% adjusted EPS growth versus 2025.
LeMaitre Vascular insider Bridget A. Ross filed to sell common stock under a Form 144. The planned sale covers 4,322 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $449,241.48, expected on July 29, 2026 and listed on NASDAQ.
The filing states that the shares relate to a stock option exercise. It also notes that 22,850,739 shares of the issuer’s common stock are outstanding. Over the prior three months, Ross sold 5,044 shares of common stock for aggregate proceeds of $560,366.40 on May 7, 2026.
LeMaitre Vascular, Inc. has a significant shareholder group consisting of First Trust Portfolios L.P., First Trust Advisors L.P., and The Charger Corporation reporting beneficial ownership of 1,175,902 shares of LeMaitre Vascular common stock, representing 5.15% of the class.
The group reports no sole voting or dispositive power. They report shared voting power over 1,170,364 shares and shared dispositive power over 1,175,902 shares, primarily through unit investment trusts and other investment vehicles. The trusts are sponsored or advised by First Trust entities, while voting is generally carried out by the trustee to mirror other shareholders. Each reporting person disclaims beneficial ownership of the reported shares.
LeMaitre Vascular director Lawrence J. Jasinski reported grants of dividend equivalent rights on existing equity awards. On 2026-06-04, he acquired several small blocks of dividend equivalent rights linked to previously granted restricted stock unit and performance share unit awards from 2023, 2024, and 2025.
Each dividend equivalent right is the economic equivalent of one share of LeMaitre Vascular common stock and will vest proportionately with the underlying awards. These are compensation-related accruals with no open-market buying or selling and no cash exercise price.
LeMaitre Vascular director John James O’Connor reported routine compensation-related grants of dividend equivalent rights. On June 4, 2026, he acquired several small awards of dividend equivalent rights tied to existing restricted stock unit and performance share unit awards granted on December 8, 2023, December 6, 2024, and December 10, 2025. Each dividend equivalent right is the economic equivalent of one share of LeMaitre Vascular common stock and carries a stated price of $0.00 per right. Following these transactions, O’Connor directly holds 5.0674 dividend equivalent rights in total, which vest proportionately with the underlying stock and performance awards rather than representing open-market purchases or sales.
Roush John A reported acquisition or exercise transactions in this Form 4 filing.
LeMaitre Vascular director John A. Roush reported routine compensation-related transactions in the form of dividend equivalent rights on June 4, 2026. Five separate grants of dividend equivalent rights were credited in fractional amounts, each tied to existing restricted stock unit and performance share unit awards granted in December 2023, 2024, and 2025. Each dividend equivalent right is the economic equivalent of one share of LeMaitre Vascular common stock and vests in step with the underlying equity awards. These awards involve no cash paid by Roush and do not reflect any open-market purchases or sales of shares.
LEMAITRE VASCULAR INC director Martha Shadan reported compensation-related awards of dividend equivalent rights tied to prior equity grants. On 2026-06-04, she acquired five derivative positions labeled as Dividend Equivalent Rights, each economically equivalent to one share of common stock and carrying no exercise price.
The rights accrued on restricted stock unit and performance share unit awards originally granted on 12/8/2023, 12/6/2024, and 12/10/2025, and will vest proportionately with those underlying awards. No open-market purchases or sales were reported, and all transactions were classified as grants or awards.
LeMaitre Vascular director Joseph P. Pellegrino Jr. reported several compensation-related grants of Dividend Equivalent Rights tied to existing equity awards. On June 4, 2026, he acquired small fractional rights on multiple restricted stock unit and performance share unit awards from prior grant dates.
Each dividend equivalent right is the economic equivalent of one share of LeMaitre Vascular common stock and vests proportionately with the underlying award. The transactions are coded as awards (not open‑market trades), so they reflect routine accrual of additional rights rather than buying or selling shares in the market.
LeBlanc Dorian Paul reported acquisition or exercise transactions in this Form 4 filing.
LeMaitre Vascular’s Chief Financial Officer, Dorian Paul LeBlanc, received additional equity-linked compensation. On June 4, 2026, he was granted 3.1523 dividend equivalent rights tied to a restricted stock unit award granted on March 10, 2025, bringing his holdings in those rights to 5.8193. He also received 2.4759 dividend equivalent rights tied to a separate restricted stock unit award granted on December 10, 2025, increasing those holdings to 13.8976 dividend equivalent rights. Each dividend equivalent right is the economic equivalent of one share of LeMaitre Vascular common stock and will vest proportionately with the related restricted stock unit awards.